Hydrocodone and Homatropine Syrup and Methyldopa Oral, Intravenous
Determining the interaction of Hydrocodone and Homatropine Syrup and Methyldopa Oral, Intravenous and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Methyldopa and HYDROcodone may have additive effects in lowering your blood pressure. You may experience headache, dizziness, lightheadedness, fainting, and/or changes in pulse or heart rate. These side effects are most likely to be seen at the beginning of treatment, following a dose increase, or when treatment is restarted after an interruption. Let your doctor know if you develop these symptoms and they do not go away after a few days or they become troublesome. Avoid driving or operating hazardous machinery until you know how the medications affect you, and use caution when getting up from a sitting or lying position. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.
MANAGEMENT: Caution is advised during coadministration of these agents. Close monitoring for development of hypotension is recommended. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.
- Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139
- Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6
- Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1
- Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40
- Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75
- Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595
Generic Name: homatropine / hydrocodone
Brand name: Hydromet, Tussigon, Hycodan, Hydrotropine, Hydromide, Hydropane
Synonyms: Homatropine and hydrocodone, Hydrocodone and Homatropine
Generic Name: methyldopa
Brand name: Aldomet
Synonyms: Methyldopa
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Hydrocodone and Homatropine Syrup-Methyldopa Tablets
- Hydrocodone and Homatropine Syrup-Methyldopate
- Hydrocodone and Homatropine Syrup-Methyldopate hydrochloride
- Hydrocodone and Homatropine Syrup-Methylene Blue
- Hydrocodone and Homatropine Syrup-Methylene blue injection
- Hydrocodone and Homatropine Syrup-Methylene blue Oral, Intravenous
- Methyldopa Oral, Intravenous-Hydrocodone and Homatropine Tablets
- Methyldopa Oral, Intravenous-Hydrocodone and ibuprofen
- Methyldopa Oral, Intravenous-Hydrocodone and Pseudoephedrine
- Methyldopa Oral, Intravenous-Hydrocodone Bitartrate
- Methyldopa Oral, Intravenous-Hydrocodone Bitartrate and Acetaminophen Oral Solution
- Methyldopa Oral, Intravenous-Hydrocodone Extended-Release Capsules